Silver-NanoParticles / MAPK Cancer Research Results

AgNPs, Silver-NanoParticles: Click to Expand ⟱
Features:
Silver NanoParticles (AgNPs)
Summary:
1.Smaller sizes are generally more bioactive due to increased surface area and enhanced tumor accumulation via the enhanced permeability and retention (EPR) effect.
2.Two relevant forms: particulate silver (AgNPs) and ionic silver (Ag⁺). There is debate regarding oral use, as Ag⁺ can precipitate as AgCl in gastric acid, reducing bioavailability; AgNPs may partially avoid this via particulate uptake and intracellular Ag⁺ release. Gastric pH may influence this equilibrium.
3. Dose example 80kg person: 1.12-2mg/day, which can be calculated based on ppm and volume taken (see below) target < 10ppm and 120mL per day (30ppm and 1L per day caused argyria 30mg/day ) (Case Report: 9‐15 ppm@120mL, i.e. 1.1mg/L to 1.8mg/L per day)
Likely 10ppm --> 10mg/L, hence if take 100mL, then 1mg/day? (for Cancer)
The current Rfd for oral silver exposure is 5 ug/kg/d with a critical dose estimated at 14 ug/kg/d for the average person.
Seems like the Cancer target range is 14ug/kg/day to 25ug/kg/day. 80Kg example: 1.12mg to 2mg “1.4µg/kg body weight. If I would have 70kg, I would want to use 100µg/day. However, for fighting active disease, I would tend to explore higher daily dose, as I think this may be too low.”
These values reflect experimental or anecdotal contexts and are not established safe or therapeutic doses.
4. Antioxidants such as NAC can counteract AgNP cytotoxicity by restoring glutathione pools and suppressing ROS-mediated mitochondrial damage.
5. In vitro studies commonly show ROS elevation in both cancer and normal cells; however, in vivo, superior antioxidant, NRF2, and repair capacity in normal tissues may confer selectivity.
6. Pathways/mechanisms of action/:
-” intracellular ROS was increased...reduction in levels of glutathione (GSH)”
- Normal-cell selectivity is partly mediated by NRF2-dependent antioxidant and detoxification responses.
- AgNPs impair mitochondrial electron transport, increasing electron leak and amplifying ROS upstream of ΔΨm collapse.
-AgNPs inhibit VEGF-driven endothelial signaling and permeability (anti-angiogenic effect)
-”upregulation of proapoptotic genes (p53, p21, Bax, and caspases) and downregulation of antiapoptotic genes (Bcl-2)”
-” upregulation of AMPK and downregulation of mTOR, MMP-9, BCL-2, and α-SMA”
-”p53 is a key player...proapoptotic genes p53 and Bax were significantly increased... noticeable reduction in Bcl-2 transcript levels”
-” p53 participates directly in the intrinsic apoptosis pathway by regulating the mitochondrial outer membrane permeabilization”
- “Proapoptotic markers (BAX/BCL-XL, cleaved poly(ADP-ribose) polymerase, p53, p21, and caspases 3, 8 and 9) increased.”
-”The antiapoptotic markers, AKT and NF-kB, decreased in AgNP-treated cells.”

Chronic accumulation and long-term systemic effects remain insufficiently characterized.

Silver NanoParticles and Magnetic Fields
Summary:
1. “exposure to PMF increased the ability of AgNPs uptake”
2. 6x improvement from AgNPs alone

could glucose capping of SilverNPs work as trojan horse?

Sodium selenite might protect against toxicity of AgNPs in normal cells.

-uncoated AgNPs can degrade the gut microbiome. PVP, citrate, green-synthesized, chitosan coating, may reduce the effect.
Similar oxidative considerations may apply to selenium compounds, though mechanisms differ.
co-ingestion with food (higher pH) favors reduction and lower Ag+ levels.
-action mechanisms of AgNPs: the release of silver ions (Ag+), generation of reactive oxygen species (ROS), destruction of membrane structure.

AgNP anticancer effects come from three overlapping mechanisms:
-Nanoparticle–cell interaction (uptake, membrane effects)
-Intracellular ROS generation
-Controlled Ag⁺ release inside cancer cells

Comparison adding Citrate Capping
| Property              | Uncapped AgNPs | Citrate-capped AgNPs |
| --------------------- | -------------- | -------------------- |
| Stability             | Poor           | Excellent            |
| Free Ag⁺              | High           | Low                  |
| Normal cell toxicity  | Higher         | Lower                |
| Cancer selectivity    | Lower          | **Higher**           |
| Mechanism specificity | Crude          | **Targeted**         |
| Storage behavior      | Degrades       | Stable               |

Rank Pathway / Target Axis Cancer Cells Normal Cells Primary Effect Notes / Cancer Relevance Ref
1 Oxidative stress / ROS generation ↑ ROS (sustained) ↑ transient ROS → ↓ net ROS after adaptation Upstream cytotoxic trigger AgNP exposure commonly elevates ROS in cancer cells, initiating downstream stress-death programs (ref)
2 Thiol buffering (GSH pool) ↓ GSH (depletion) ↔ or transient ↓ with recovery Loss of redox buffering Colon cancer model: AgNPs induce oxidative cell damage through inhibition/depletion of reduced glutathione with downstream mitochondrial apoptosis (ref)
3 Mitochondrial ETC / respiration ↓ ETC efficiency; ↑ electron leak ↔ mild inhibition with recovery Bioenergetic destabilization ETC impairment amplifies ROS, precedes ΔΨm loss, and contributes to ATP collapse in cancer cells
4 Mitochondrial integrity (ΔΨm / MMP) ↓ ΔΨm ↔ largely preserved Mitochondrial dysfunction Breast cancer model: AgNP exposure dissipates mitochondrial membrane potential during cytotoxic progression (ref)
5 Intrinsic apoptosis (caspase cascade) ↑ caspase-dependent apoptosis ↔ minimal activation Programmed cell death Colon cancer model: “silver-based nanoparticles” induce apoptosis mediated through p53 (apoptosis direction shown) (ref)
6 Genotoxic stress / DNA damage ↑ DNA damage ↑ damage at high dose with efficient repair Checkpoint/death signaling Study documents AgNP-mediated DNA damage; susceptibility increases with impaired DNA repair capacity (ref)
7 ER stress / UPR (CHOP-dependent) ↑ ER stress → apoptosis ↑ adaptive UPR (no CHOP) Proteotoxic stress signaling Breast cancer cells: AgNPs induce “irremediable” ER stress leading to UPR-dependent apoptosis (ref)
8 Autophagy program ↑ autophagy (protective) ↑ adaptive autophagy Stress adaptation AgNPs induce autophagy in cancer cells; inhibiting autophagy enhances AgNP anticancer killing (ref)
9 Autophagic flux / lysosomal function ↓ flux (lysosomal defect) ↔ preserved flux Autophagic failure AgNP-induced lysosomal dysfunction drives autophagic flux defects (LC3-II accumulation) (ref)
10 NRF2 antioxidant response ↔ insufficient activation ↑ NRF2 activation Adaptive redox defense NRF2 activation in normal cells restores GSH and antioxidant enzymes, limiting toxicity
11 Stress MAPK (p38) / checkpoint signaling ↑ p38 → arrest/apoptosis ↑ transient p38 → recovery Stress signaling Jurkat T-cell model shows p38 MAPK activation with DNA damage and apoptosis (ref)
12 Angiogenesis / invasion (VEGF, NF-κB-linked) ↓ angiogenesis / ↓ invasion ↔ minimal effect Anti-angiogenic / anti-invasive AgNPs inhibit VEGF-induced permeability and invasion in tumor models (ref)


MAPK, mitogen-activated protein kinase: Click to Expand ⟱
Source: CGL-CS
Type:
Mitogen-activated protein kinases (MAPKs) are a group of proteins involved in transmitting signals from the cell surface to the nucleus, playing a crucial role in various cellular processes, including growth, differentiation, and apoptosis (programmed cell death).

MAPK Pathways: The MAPK family includes several pathways, the most notable being:
1.ERK (Extracellular signal-Regulated Kinase): Often associated with cell proliferation and survival.
2.JNK (c-Jun N-terminal Kinase): Typically involved in stress responses and apoptosis.
3.p38 MAPK: Associated with inflammatory responses and apoptosis.

Inhibitors: Targeting the MAPK pathway has become a strategy in cancer therapy. For example, BRAF inhibitors (like vemurafenib) are used in treating melanoma with BRAF mutations.
Altered Expression Levels:
Overexpression: Many cancers exhibit overexpression of MAPK pathway components, such as RAS, BRAF, and MEK. This overexpression can lead to increased signaling activity, promoting cell proliferation and survival.
Downregulation: In some cases, negative regulators of the MAPK pathway (e.g., MAPK phosphatases) may be downregulated, leading to enhanced MAPK signaling.
The expression levels of MAPK pathway components can serve as biomarkers for cancer diagnosis, prognosis, and treatment response. For example, high levels of phosphorylated ERK (p-ERK) may indicate active MAPK signaling and poor prognosis in certain cancers.

Numerous reports indicate that the MAPK pathway plays a major role in tumor progression and invasion, while inhibition of MAPK signaling reduces invasion.
Scientific Papers found: Click to Expand⟱
5142- AgNPs,    Biosynthesized Protein-Capped Silver Nanoparticles Induce ROS-Dependent Proapoptotic Signals and Prosurvival Autophagy in Cancer Cells
- in-vitro, CRC, HUH7
ROS↑, Apoptosis↑, eff↑, ChemoSen↑, EPR↑, Casp↑, MAPK↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

ROS↑, 1,  

Cell Death ⓘ

Apoptosis↑, 1,   Casp↑, 1,   MAPK↑, 1,  

Angiogenesis & Vasculature ⓘ

EPR↑, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 1,   eff↑, 1,  
Total Targets: 7

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: MAPK, mitogen-activated protein kinase
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:153  Target#:181  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page